Merck (MRK) Retained Earnings (2009 - 2026)
Merck (MRK) posted quarterly Retained Earnings of -$4.1 billion for Q1 2026, up 18.23% year-over-year from -$3.4 billion in Q1 2025, and up 5.3% quarter-over-quarter from -$4.3 billion in Q4 2025.
Merck (MRK) Retained Earnings (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Retained Earnings for 18 consecutive years, with -$4.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 18.23% year-over-year to -$4.1 billion; the TTM figure through Mar 2026 stood at -$4.1 billion (up 18.23% YoY), while the FY2025 annual figure was -$4.3 billion, up 13.31% from the prior year.
- Retained Earnings improved to -$4.1 billion in Q1 2026 per MRK's latest filing, from -$4.3 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $72.2 billion in Q3 2025 and bottomed at -$5.4 billion in Q2 2024.
- Historically, Retained Earnings has averaged $30.4 billion across 5 years, with a median of $54.2 billion in 2023.
- Annual changes were most pronounced in 2023 — Retained Earnings soared 1519.98% — and 2024, when it sank 109.89%.
- Merck's Retained Earnings stood at $61.1 billion in 2022, then slumped by 108.45% to -$5.2 billion in 2023, then grew by 4.19% to -$4.9 billion in 2024, then climbed by 13.31% to -$4.3 billion in 2025, then increased by 5.3% to -$4.1 billion in 2026.
- Business Quant data shows MRK's Retained Earnings at -$4.1 billion in Q1 2026, -$4.3 billion in Q4 2025, and $72.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 171.67 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -17.33 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 63.27 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 12.59 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -22.28 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 9.53 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 112.09 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 15.38 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 63.27 Bn |
| Mar 31, 2026 | -4.06 Bn |
| Dec 31, 2025 | -4.29 Bn |
| Sep 30, 2025 | 72.23 Bn |
| Jun 30, 2025 | 68.48 Bn |
| Mar 31, 2025 | -4.97 Bn |
| Dec 31, 2024 | -4.95 Bn |
| Sep 30, 2024 | 61.38 Bn |
| Jun 30, 2024 | -5.36 Bn |
| Mar 31, 2024 | 56.70 Bn |
| Dec 31, 2023 | -5.16 Bn |
| Sep 30, 2023 | -4.92 Bn |
| Jun 30, 2023 | 54.20 Bn |
| Mar 31, 2023 | 62.04 Bn |
| Dec 31, 2022 | 61.08 Bn |
| Sep 30, 2022 | 59.93 Bn |
| Jun 30, 2022 | 58.44 Bn |
| Mar 31, 2022 | -4.37 Bn |
| Dec 31, 2021 | 53.70 Bn |
| Sep 30, 2021 | 51.69 Bn |